3 brokers N1 SINGER, CANACCORD,STIFEL NICHOLAS have all reiterated their buy recommendations at 96P 73P 103P respectively.
21 Aug '15
Yeah it's a definite overreaction. Trading results released will hopefully rest some fears. Plenty of upside potential. And we've barely touched the tip of the iceberg. Sp should stabilise around 70. So not much point in selling. I've been long on this one for a while
21 Aug '15
I think a bit of profit taking as the rest of the market is in a tailspin.lots more to come from vernalis a good buying opportunity i would have thought.always have to be aware of disappointing news investing in biotech's and adverse share price reactions.
21 Aug '15
Are you seriously thinking about bailing? VER is about to make profit for the first time. You should be investing more if anything. We are still yet to see the fruits of the cough cold medicine. The latest news is a very minor setback and in the grand scheme of things means actually very little. You're always going to get R&D projects that are scrapped. It's just the nature of the sector.
20 Aug '15
Proof of Content study update
Announces the results from a Phase II proof-of-concept (POC) study of V158866, its fatty acid amide hydrolase (FAAH) inhibitor, which is being investigated as a treatment for neuropathic pain as a result of spinal cord injury. In the randomised, double-blind, placebo-controlled, two-period cross-over study, although dosing of V158866 resulted in elevated endocannabinoid levels, on an intent-to-treat basis the study failed to meet its pain reduction primary endpoint. Treatment with V158866 did however show a trend towards efficacy on a per protocol basis (p=0.054) and was generally well tolerated. Consistent with its strategy of becoming a commercial business, Vernalis is not planning to make any further investment in this programme and will seek to realise its potential value through partnering. A previous Phase I study provided encouraging data in evaluating the safety, tolerability and pharmacokinetic and pharmacodynamic effects of the compound. Ian Garland, CEO of Vernalis commented "The goal of this study was to identify a therapeutic setting for this programme. Its completion ends the investment in our NCE pipeline and we aim to partner the remaining unpartnered programmes to realise value where possible. The key focus of the organisation remains the transition of Vernalis to a commercial company, with the forthcoming launch of Tuzistra™ XR, our extended release cough cold product for the US prescription market, which is progressing as planned ".
18 Aug '15
very nice appointment ,Vernalis plc - Appointment of Non-Executive Director Vernalis plc announces that Ms Lisa Amster Schoenberg, aged 48, has been appointed to the Board as a Non-Executive Director with effect from 1 September 2015. Ms Schoenberg has extensive marketing experience of pharmaceutical products in both primary and secondary care in the US. For the past two years, she has acted as pharmaceutical marketing consultant to a number of organisations. From 1993 until 2013 Ms Schoenberg worked for AstraZeneca Pharmaceuticals (US) in a number of senior marketing positions, culminating as VP Sales & Marketing, Growth Brands USA. After graduating from the University of Michigan in 1988, Ms Schoenberg joined Amster & Co as Financial Analyst. She then undertook an MBA at Wharton School, University of Pennsylvania, specialising in Healthcare Management and Marketing, before joining AstraMerck in 1993. Peter Fellner, Chairman of Vernalis plc, commented: "I am delighted to welcome Lisa to the Vernalis Board. Her experience in launching and commercialising products in the US market in both primary care and speciality medicines and her knowledge of the changing US marketing environment and how it is likely to evolve will be invaluable for the Board. We look forward to her contribution, as we continue to build value for Vernalis' shareholders." spup
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.